Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ -159,001
▼ 628% vs 2025
Profit
Caution€ -862,364
▼ 3346% vs 2025
Debts
Low€ 65,695
▲ 911% vs 2025
Gimv Life Sciences Invest 2024 from Antwerpen, company number BE1019848694, closed financial year 2025 with a result of € -862,364 after tax. For that financial year Gimv Life Sciences Invest 2024 recorded a gross margin of € -159,001 and equity of € 15.6 million. Compared with financial year 2025, the result moved from € -25,022 to € -862,364. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
What happened at Gimv Life Sciences Invest 2024?
What happened at Gimv Life Sciences Invest 2024 in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Koen Dejonckheere stepped down as director. NBB
- Edmond Bastijns stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 25,022. Source: NBB ↗
- Hawoka became a director. NBB
- Kristof Vande Capelle stepped down as director. NBB
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
- Kristof Vande Capelle became a director. NBB
In short
From € 25,022 loss in 2025 to € 862,364 loss in 2025.
A new publication or filing at Gimv Life Sciences Invest 2024? We notify you, reason included.
Follow Gimv Life Sciences Invest 2024Need more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind Gimv Life Sciences Invest 2024 is Hawoka. The shares are held by Gimv 2024 Holding BV (99.3%), Gimv 2024 Poolco BV (0.5%), Gimv NV (0.2%) and . Derden (0%). It owns 10.9% of Kivu Bioscience Inc and 10.9% of Exciva GMBH itself.
Directors
According to the 2025 annual accounts
Director · represented by Kristof Vande Capelle
Also active at: ADVIESBEHEER GIMV HEALTH & CARE 2013, Adviesbeheer Gimv Connected Consumer 2013, ADVIESBEHEER GIMV SMART INDUSTRIES 2013 +15 more
since 2025
Kristof Vande Capelle
Director
since 2025 · until 2025
Koen Dejonckheere
Director
since 2025 · until 2028
Director · represented by Edmond Bastijns
Also active at: ADVIESBEHEER GIMV HEALTH & CARE 2013, Adviesbeheer Gimv Connected Consumer 2013, ADVIESBEHEER GIMV SMART INDUSTRIES 2013 +14 more
since 2025 · until 2028
Shareholders
Participations
Kivu Bioscience Inc
10.9%
Exciva GMBH
10.9%
Establishments
Establishment units
Physical locations of this company
Karel Oomsstraat 37
2018 Antwerpen
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 55 companies are registered at this address.
Gimv same network
€ 8.6 million revenue · 2025
Jan Moonen
€ 686,931 revenue · 2025
Wilson
€ 123,804 gross margin · 2025
San Michel
€ 64,813 gross margin · 2025
Immo Alfa
€ 383,148 gross margin · 2025
+50 more
Details
- Company number
- 1019.848.694
- VAT number
- BE 1019.848.694
- Registered office
- Karel Oomsstraat 37, 2018 Antwerpen
- Names & denominations
- Gimv Life Sciences Invest 2024
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 February 2025
- Peppol
- Active · Active since 20 Apr 2026
- Activities · NACE
Activiteiten van holdings